Pyxis Oncology
PYXS
92 hedge funds and large institutions have $102M invested in Pyxis Oncology in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 17 reducing their positions, and 9 closing their positions.
625% more call options, than puts
Call options by funds: $2.02M | Put options by funds: $279K
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
71% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 17
15% more funds holding
Funds holding: 80 → 92 (+12)
10% more capital invested
Capital invested by funds: $93.1M → $102M (+$9.26M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.85% less ownership
Funds ownership: 47.77% → 46.93% (-0.85%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.99M |
| 2 |
PA
Perceptive Advisors
New York
|
+$1.78M |
| 3 |
6CM
683 Capital Management
New York
|
+$1.45M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.34M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.18M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.47M |
| 3 |
SCM
Superstring Capital Management
New York
|
-$1.6M |
| 4 |
SC
Stempoint Capital
New York
|
-$1.23M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$823K |
PYXS Hedge Fund Activity: Q3 2024 in Review
92 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q3 2024, worth a combined $102M — up 9.9% from $93.1M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new PYXS positions and 9 closed out — a net gain of 13 holders — while 29 added to existing stakes and 17 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.99M. The largest seller was Balyasny Asset Management, cutting an estimated $8.18M.
- 92 institutional investors held Pyxis Oncology (PYXS) as of Q3 2024, up from 80 in Q2 2024.
- Funds reported $102M of Pyxis Oncology stock for Q3 2024, up 9.9% quarter-over-quarter.
- 22 funds opened new Pyxis Oncology positions in Q3 2024 and 9 closed out, a net change of +13 holders.
- The largest Pyxis Oncology buyer in Q3 2024 was Millennium Management, an estimated $1.99M added.
- The largest Pyxis Oncology seller in Q3 2024 was Balyasny Asset Management, an estimated $8.18M sold.
Based on aggregated 13F filings for Q3 2024.